Avacc 31
Alternative Names: Avacc-31Latest Information Update: 03 May 2024
At a glance
- Originator Intravacc; The German Center for Neurodegenerative Diseases
- Class Conjugate vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
Most Recent Events
- 04 Apr 2024 Avacc 31 is available for licensing as of 04 Apr 2024. https://www.intravacc.nl/services/pipeline
- 04 Apr 2024 Preclinical trials in Amyotrophic lateral sclerosis in Germany (SC) (Intravacc pipeline, April 2024)
- 04 Apr 2024 Preclinical trials in Amyotrophic lateral sclerosis in Netherlands (SC) (Intravacc pipeline, April 2024)